Diligence memo · auto-generated · as of July 2, 2026
Orpheus Bioscience, Inc.
Orpheus Bioscience, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Orpheus Bioscience, Inc. operates in Biotech, based in MANASSAS.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Orpheus Bioscience, Inc. has raised $4.4M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.2M on 2019-06-11.
Most recent recorded round closed around 2019-06-11.
Valuation (modeled)modeled
Provath models Orpheus Bioscience, Inc. at approximately $140M (range $2.3M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.59× the median modeled value of Seed Biotech companies in 2019–2021 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 7.1 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 79% of Biotech peers (233 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: OneThree Biotech, Inc., Phloem Biotech, Inc., Meridian Biotech, LLC, Sixfold Bioscience Inc., iGenomX International Genomics Corp.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.